Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis.
A paradoxical increase in circulating Aspergillus antigen was observed during treatment with caspofungin in a patient with proven invasive aspergillosis. With the exception of treatment with the echinocandin, no other factors were found that might explain this clinical observation, which was supported by experiments done in vitro.
Klont
Rocus R
RR
Department of Medical Microbiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. r.klont@mmb.umcn.nl
Mennink-Kersten
Monique A S H
MA
Ruegebrink
Dorien
D
Rijs
Antonius J M M
AJ
Blijlevens
Nicole M A
NM
Donnelly
J Peter
JP
Verweij
Paul E
PE
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D000946:Antigens, Fungal / Q000097:blood*; D001228:Aspergillosis / Q000188:drug therapy* / Q000276:immunology; D001232:Aspergillus fumigatus / Q000276:immunology*; D000077336:Caspofungin; D054714:Echinocandins; D005656:Fungal Proteins / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D055666:Lipopeptides; D008172:Lung Diseases, Fungal / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D009190:Myelodysplastic Syndromes / Q000628:therapy; D010456:Peptides, Cyclic / Q000627:therapeutic use*
D000935:Antifungal Agents; D000946:Antigens, Fungal; D054714:Echinocandins; D005656:Fungal Proteins; D007166:Immunosuppressive Agents; D055666:Lipopeptides; D010456:Peptides, Cyclic; C007572:echinocandin B; D000077336:Caspofungin